These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1675452)

  • 1. R(-)2-fluoro-N-n-propylnorapomorphine: a very potent and D2-selective dopamine agonist.
    Baldessarini RJ; Kula NS; Gao Y; Campbell A; Neumeyer JL
    Neuropharmacology; 1991 Jan; 30(1):97-9. PubMed ID: 1675452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.
    Neumeyer JL; Gao YG; Kula NS; Baldessarini RJ
    J Med Chem; 1990 Dec; 33(12):3122-4. PubMed ID: 2147956
    [No Abstract]   [Full Text] [Related]  

  • 3. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
    Gao YG; Baldessarini RJ; Kula NS; Neumeyer JL
    J Med Chem; 1990 Jun; 33(6):1800-5. PubMed ID: 1971309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.
    Ferre S; von Euler G; Johansson B; Fredholm BB; Fuxe K
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7238-41. PubMed ID: 1678519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
    Gao YG; Ram VJ; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1990 Jan; 33(1):39-44. PubMed ID: 2136919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Cox RF; Waszczak BL
    Brain Res; 1993 Jun; 613(1):32-42. PubMed ID: 8102308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism.
    Ross SB
    J Neurochem; 1991 Jan; 56(1):22-9. PubMed ID: 1824780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vanadate inhibits agonist binding to D2 dopamine receptor.
    Elazar Z; Fuchs S
    J Mol Neurosci; 1991; 3(1):1-6. PubMed ID: 1679343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
    Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
    J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
    Andersen PH; Nielsen EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous distribution of dopamine D2 receptors within the rat striatum as revealed by autoradiography of [3H]N-n-propylnorapomorphine binding sites.
    Dubois A; Scatton B
    Neurosci Lett; 1985 Jun; 57(1):7-12. PubMed ID: 3162114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of (-)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens.
    Barnes JM; Barnes NM; Costall B; Naylor RJ
    Neuropharmacology; 1990 Apr; 29(4):327-36. PubMed ID: 1971430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Oxygenated N-alkyl- and N,N-Dialkyl-2-amino-1-methyltetralins. Effects of structure and stereochemistry on dopamine-D2-receptor affinity.
    Grol CJ; Nordvall G; Johansson AM; Hacksell U
    J Pharm Pharmacol; 1991 Jul; 43(7):481-5. PubMed ID: 1682460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein.
    Cumming P; Wong DF; Gillings N; Hilton J; Scheffel U; Gjedde A
    J Cereb Blood Flow Metab; 2002 May; 22(5):596-604. PubMed ID: 11973432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correspondency between different affinity states and target size of the bovine striatal D2 dopamine receptor.
    Kuno T; Tanaka C
    Biochem Biophys Res Commun; 1983 Nov; 117(1):65-70. PubMed ID: 6197972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
    Si YG; Gardner MP; Tarazi FI; Baldessarini RJ; Neumeyer JL
    J Med Chem; 2008 Feb; 51(4):983-7. PubMed ID: 18251489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.